Galapagos increases share capital through subscription right exercises
March 18 2022 - 5:01PM
Mechelen, Belgium; 18 March
2022,
22.01
CET; regulated
information – Galapagos NV (Euronext & NASDAQ:
GLPG) announces a share capital increase arising from
subscription right exercises.
Galapagos issued 95,500 new ordinary shares on
18 March 2022, for a total capital increase (including issuance
premium) of €2,159,600.00.
Pursuant to the subscription right exercise
program of Galapagos’ management board, members of the management
board automatically are committed to exercise a minimum number of
subscription rights, subject to certain conditions. In accordance
with the rules of this program, our CEO Onno van de Stolpe
exercised 15,000 subscription rights and one management board
member exercised 5,000 subscription rights. In total our CEO
exercised 50,000 subscription rights and the aforementioned
management board member 10,000 subscription rights, as these
subscription rights are due to expire in July 2022.
In accordance with Belgian transparency
legislation1, Galapagos notes that its total share capital
currently amounts to €355,098,660.11, the total number of
securities conferring voting rights amounts to 65,648,221, which is
also the total number of voting rights (the “denominator”), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (formerly known as
warrants) to subscribe to not yet issued securities conferring
voting rights is (i) 8,322,710 subscription rights under several
outstanding employee subscription right plans, which equals
8,322,710 voting rights that may result from the exercise of those
subscription rights, and (ii) one subscription right issued to
Gilead Therapeutics to subscribe for a maximum number of shares
that is sufficient to bring the shareholding of Gilead and its
affiliates to 29.9% of the actually issued and outstanding shares
after the exercise of the subscription right. This excludes the
1,000,000 subscription rights of Subscription Right Plan 2022 (B),
which were created subject to acceptance. Galapagos does not have
any convertible bonds or shares without voting rights
outstanding.
About GalapagosGalapagos NV
discovers, develops, and commercializes small molecule medicines
with novel modes of action. Our pipeline comprises discovery
through Phase 3 programs in inflammation, fibrosis, and other
indications. Our ambition is to become a leading global
biopharmaceutical company focused on the discovery, development,
and commercialization of innovative medicines. More information at
www.glpg.com.
ContactInvestors:Sofie Van
GijselHead of Investor Relations+1 781 296 1143
Sandra CauwenberghsDirector Investor Relations+32 495 58 46
63ir@glpg.com
Media:Marieke VermeerschHead of Corporate
Communication+32 479 490 603communications@glpg.com
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
1 Belgian Act of
2 May 2007 on the disclosure of major shareholdings in issuers
whose shares are admitted to trading on a regulated market
- Galapagos increases share capital through subscription right
exercises
Galapagos (EU:GLPG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Sep 2023 to Sep 2024